MKMarwa Mohamed Ibrahim Khalil

Marwa Mohamed Ibrahim Khalil

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marwa Mohamed Ibrahim Khalil has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessment of IL-27 T4730C polymorphism and its serum levels in neonatal cholestasis patients

    by Amira Samy Elmaghraby, Salma Abdel Megeed Nagi, Amal M. Dawoud, Marwa M. Khalil, Sania Ali Yehia, Heba Abdelhalim, Amany E. Elashkar

    Background: The immune system and many genes have been linked to bile tract damage in neonatal cholestasis (NC), resulting in liver retention of biliary contents. The most commonly recognized cause of NC is biliary atresia (BA). Objectives: The study investigated the effect of the IL27 rs181206 polymorphism on NC risk and its potential association with blood IL-27 levels. Methodology: This study included 41 NC patients (20 BA and 21 non-BA), and 20 healthy controls. The diagnosis of NC has been confirmed by a cholestasis workup that includes radiographic evidence, laboratory-based analysis, and clinical observations. The genotype of the variation IL-27 rs181206 was assessed using a pre-made Taqman test. Serum levels of IL27 were determined using a double antibody sandwich enzyme-linked immunosorbent assay. Results: Compared to controls, individuals with NC had a greater frequency of the T allele (98.8% vs. 60%) ( P value 0.002). Those with the TT genotype had a 17.14-fold increased risk of developing NC in the dominant model [OR, 17.14 (95% CI, 1.89 to 155.14); P = 0.004]. NC infants had significantly higher serum levels of IL-27 (98.180 ± 34.96 for BA and 100.757 ± 46.42 for non-BA) than controls (76.070 ± 5.8650). However, IL-27 serum levels did not differ significantly among different genotypes. Conclusion: The T allele and TT genotype could increase the risk of NC susceptibility. Understanding IL27’s role in NC pathogenesis can help to use it as a diagnostic marker or therapeutic target.

  • Targeting the PI3K/Akt/mTOR and Nrf2 signaling axis with berberine: a novel strategy for attenuating diabetic cardiomyopathy

    by Omnia Ameen, Eman M. Sweed, Mona A. Kora, Asmaa Abdelkarim Kenawy, Marwa M. Khalil, Suzan A. Khodir

    Diabetic cardiomyopathy (DCM) is a major contributor to heart failure in patients with diabetes. Although berberine (BBR) exhibits broad metabolic and cardiovascular benefits, its mechanistic role in DCM remains incompletely defined. Cardiovascular function was assessed using arterial blood pressure (ABP), electrocardiography (ECG), and echocardiography. Biochemical analyses included glycemic indices, lipid profile, oxidative stress markers, inflammatory cytokines, and cardiac injury biomarkers. Cardiac and aortic tissues were evaluated for calcium (Ca2⁺) content, gene expression by RT-PCR, and immunohistochemical changes. DCM rats exhibited significant increases in ABP, left ventricular internal diameter, fasting glucose, HbA1c, cholesterol, triglycerides, LDL-C, malondialdehyde, tumor necrosis factor-α, interleukin-17, cardiac enzymes, Caspase-3 expression, and myocardial and aortic fibrosis, accompanied by marked ECG abnormalities. Conversely, ejection fraction, fractional shortening, serum insulin, HDL-C, superoxide dismutase activity, interleukin-10 levels, cardiac Ca2⁺ content, and expression of phosphoinositide 3-kinase (PI3K), protein kinase B (Akt), mammalian target of rapamycin (mTOR), nuclear factor erythroid 2-related factor 2 (Nrf2), and PTEN-induced putative kinase protein 1 (PINK1) were significantly reduced. Combined insulin and BBR treatment produced greater improvement in cardiac structure, function, and molecular signaling than either treatment alone. Berberine, particularly as an adjunct to insulin therapy, effectively attenuates DCM by reducing hyperglycemia, dyslipidemia, oxidative stress, inflammation, fibrosis, and apoptosis, while enhancing mitophagy and cardiac Ca2⁺ homeostasis. These effects are mediated, at least in part, through the coordinated modulation of the PI3K/Akt/mTOR and Nrf2 signaling pathways.

  • Dapagliflozin and crocin ameliorate DOX-induced cardiotoxicity in rats via activating the Nrf-2/HO-1/NQO1 pathway: a comparative study

    by Anwaar M. Shaban, Eman A. Ali, Marwa Mohamed Ibrahim Khalil, Marwa Omar, Yousra Ali Rohem Al-Ghalban, Eman I. El-Gizawy

    Doxorubicin- (DOX-) related cardiotoxicity is a progressive degenerative loss of cardiac muscle mass and strength. This investigation aims to compare the anticipated cardioprotective effects of crocin (Cr) and dapagliflozin (DAPA) against DOX-induced cardiotoxicity, and to assess their effects on apoptosis and the Nrf-2/HO-1/NQO1 pathway. Forty Wistar male rats were randomly divided into four groups: The control group received distilled water (DW) by oral gavage. The DOX group was given DOX 3 times/week, i.p., 2.5 mg/kg for three weeks. The Cr + DOX-treated group was intraperitoneally injected with Cr daily, concomitantly with DOX, for 12 weeks. The DAPA + DOX-treated group received DAPA daily by oral gavage concomitantly with DOX for 12 weeks. Initial fasting blood glucose (FBG), body weight, vital signs, systolic blood pressure (SBP), and electrocardiography (ECG) were recorded and then repeated monthly throughout the study period. After 12 weeks, biochemical analyses were performed. Moreover, histopathological and immunohistochemical examinations of cardiac tissue were conducteed. DOX significantly affected FBG and increased oxidative stress markers and proinflammatory cytokines, with hypotension, bradycardia, ECG changes, and downregulation of antioxidant genes (Nrf-2/HO-1/NQO1) mRNA. Besides, cardiac biomarkers deteriorated. Administration of either Cr or DAPA resulted in significant improvements in all tested parameters compared with DOX. However, the DAPA + DOX group showed greater improvement, particularly in some parameters. DAPA is a promising new cardioprotective medication against DOX-related cardiotoxicity. Cardiotoxicity is better controlled with DAPA than Cr by suppressing oxidative stress, apoptosis, and upregulation of the antioxidant Nrf-2/HO-1/NQO1 genes.


  • The association between single-nucleotide polymorphisms of FDPS Rs2297480 and MECP2 Rs2734647 genes and the susceptibility to rheumatoid arthritis in Egyptian patients

    by Nesreen G. Elhelbawy, Basant F. Saad, Ibrahim El Tantawy El Sayed, Bishoy El-Aarag, Marwa M. Khalil

    Rheumatoid arthritis (RA) has a complex etiology that involves environmental and genetic variables. The identification of new genetic connections contributes to accelerating the development of customized medications to treat or delay the progression of diseases. We aimed to assess the relationship between rheumatoid arthritis susceptibility and genetic variations of the Farnesyl Diphosphate Synthase (FDPS) and methyl CpG binding protein 2 (MECP2) genes. 100 patients with rheumatoid arthritis and 100 healthy control subjects participated in this case-control research. Genetic analyses for single-nucleotide polymorphisms (SNPs) in the FDPS and MeCP2 genes were performed on the patients. In terms of FDPS genetic polymorphisms, the sick group had greater frequencies of the TG and GG genotypes, whereas the control group had a higher frequency of the TT genotype. The CC genotype was more common in the control group, but the TC and TT genotypes were more common in the sick group concerning MECP2 genetic polymorphisms. For rheumatoid arthritis, the FDPS (rs2297480) TT genotype seemed to be protective. An increased risk of rheumatoid arthritis was linked to the MECP2 (rs2734647) TT genotype, but the CC genotype seemed to be protective against the condition.

  • Pivotal role of interleukin 27 serum level and missense variant (rs181206) in multiple sclerosis

    by Amany E. Elashkar, Marwa M. Khalil, Mona S. Elkholy, Eman Samy, Sanaa S Hamam, Amira Samy Elmaghraby

    The incidence of multiple sclerosis (MS) has increased in recent years. Its pathogenesis involves the interaction between various elements, with interleukin 27 (IL-27) playing a key role in autoimmunity. The presence of the IL-27 receptor on astrocytes emphasizes its involvement in the disease's progression. The study aims to investigate possible associations between IL27 rs181206, serum level of IL27, and the development of MS. The study comprised 70 MS patients and 70 seemingly healthy controls. They were genotyped for IL27 rs181206 using the Taqman allelic discrimination approach, and their serum IL27 levels were estimated using ELISA. The frequency of TT genotype, T allele, and IL27 serum level were significantly higher among MS patients compared to controls. There was no significant difference between IL27 serum levels among different genotypes in both MS patients and controls; however, individuals with TT genotype showed higher levels of IL27 than those with CC genotype. TT genotype and T allele can increase the risk of developing MS. On the other hand, carrying the C allele may be associated with a lower risk of MS development. Understanding IL27 genetics and epistatic interactions can help clarify IL27's role in MS pathogenesis and utilize it as a therapeutic target.

  • Vit D mitigates metabolic syndrome-induced hepatic damage via antioxidant, anti-inflammatory, and AMPK/PI3K signaling pathways in rats

    by Suzan A. Khodir, Eman M. Sweed, Nahla M. Badr, Nader G. Zaki, Marwa M. Khalil, Marwa M. Adel

    Metabolic syndrome (MetS) involves insulin resistance and dyslipidemia. To evaluate vitamin D's (Vit D) hepatoprotective role in MetS and its mechanisms. Thirty male rats were divided into MetS, MetS + Vit D, and control groups. We measured arterial blood pressure (ABP), body weight, fat, homeostatic Model Assessment for Insulin Resistance (HOMA-IR), glycemic/lipid profiles, liver enzymes, oxidative stress (Malondialdehyde, superoxide dismutase), inflammation (Tumor necrosis factor; TNF-α, matrix metalloproteinase; MMP9, Glial fibrillary acidic protein; GFAP), and AMP-activated protein kinase/Phosphoinositide 3-kinase (AMPK/PI3K) expression. MetS increased oxidative stress, TNF-α, liver enzymes, HOMA-IR, and ABP while reducing adiponectin and AMPK/PI3K. Vit D reversed these effects, suppressing GFAP/MMP9 and restoring metabolic balance. Conclusion: Vit D mitigates MetS-induced liver damage via AMPK/PI3K activation, exerting antioxidant and anti-inflammatory effects.


  • Open Access

    Neuroprotective Effect of Maresin-1 in Rotenone-Induced Parkinson’s Disease in Rats: The Putative Role of the JAK/STAT Pathway

    by Suzan A. Khodir, Eman M. Sweed, Manar A. Faried, Doaa M. Abo Elkhair, Marwa M. Khalil, Khaled Hatem Afifi, Dalia Fathy El Agamy

    Exposure to rotenone results in similar pathophysiological features as Parkinson’s disease. Inflammation and oxidative stress are essential to PD pathogenesis. Maresin-1 has potent anti-inflammatory properties and promotes the regression of inflammation function. The current study aimed to evaluate the protective effects of Maresin-1 (MaR1) in rotenone (ROT)-induced PD and whether this protective role is associated with the initiation of the Janus kinase (JAK)-signal transducers and activator of transcription (STAT) signaling pathway. Thirty male Wister rats were classified into control, ROT-treated, and ROT + MaR1-treated groups. Rats underwent rotarod, open field, grip strength, and stepping tests as part of their motor behavioral evaluation. Serum glial cell-derived neurotrophic factor (GDNF) and striatal dopamine, acetylcholine, malondialdehyde (MDA), reduced glutathione (GSH), TNF-α, IL-6, and IL-1β were evaluated. Expression of JAK1 and STAT3 genes was assessed in striatum. Then, the tissue was subjected to histological and immunohistochemical evaluation for caspase-3, GFAP, and NF-kB. The administrated group with rotenone showed significant motor behavioral impairment. This was accompanied by reduced levels of GDNF and dopamine and increased levels of acetylcholine, as well as augmented oxidative stress and inflammatory biomarkers and reduced antioxidant activity. Inflammatory pathways (JAK1/STAT3, caspase-3, and NF-kB) were upregulated. Histopathological changes and upregulation in GFAP immunopositive reaction were observed. Remarkably, MaR1 treatment effectively alleviated behavior, histopathological changes, and biochemical alterations induced by ROT. MaR1 exerts protective effects against ROT-induced PD by its anti-inflammatory, antiapoptotic, and antioxidant properties. MaR1 mechanisms of action may involve modulation of pathways such as JAK/STAT.


  • Open Access

    Comparing the efficacy of concomitant treatment of resistance exercise and creatine monohydrate versus multiple individual therapies in age related sarcopenia

    by Eman I. Elgizawy, Ghada S. Amer, Eman A. Ali, Fatma S. Alqalashy, Marwa M. Ibrahim, Asmaa A. Abdel Latif, Anwar M. Shaban

    Aging-related sarcopenia is a degenerative loss of strength and skeletal muscle mass that impairs quality of life. Evaluating NUDT3 gene and myogenin expression as new diagnostic tools in sarcopenia. Also, comparing the concomitant treatment of resistance exercise (EX) and creatine monohydrate (CrM) versus single therapy by EX, coenzyme Q10 (CoQ10), and CrM using aged rats. Sixty male rats were equally divided into groups. The control group, aging group, EX-treated group, the CoQ10 group were administered (500 mg/kg) of CoQ10, the CrM group supplied (0.3 mg/kg of CrM), and a group of CrM concomitant with resistance exercise. Serum lipid profiles, certain antioxidant markers, electromyography (EMG), nudix hydrolase 3 (NUDT3) expression, creatine kinase (CK), and sarcopenic index markers were measured after 12 weeks. The gastrocnemius muscle was stained with hematoxylin–eosin (H&E) and myogenin. The EX-CrM combination showed significant improvement in serum lipid profile, antioxidant markers, EMG, NUDT3 gene, myogenin expression, CK, and sarcopenic index markers from other groups. The NUDT3 gene and myogenin expression have proven efficient as diagnostic tools for sarcopenia. Concomitant treatment of CrM and EX is preferable to individual therapy because it reduces inflammation, improves the lipid serum profile, promotes muscle regeneration, and thus has the potential to improve sarcopenia.